2014 Issues   /   Pharmacy

Approval of Topamax for Migraines Extended to Adolescents

By U.S. Medicine

TITUSVILLE, NJ — Food and Drug Administration approval of Topamax (topiramate) for migraine headaches prophylaxis has been extended to adolescents ages 12 to 17. It was the first FDA approval of a drug for migraine prevention in this age group.

Topamax, which is taken on a daily basis to reduce the frequency of migraine headaches, was first approved by the FDA in 1996 to prevent seizures and then approved for migraine prevention in adults 10 years ago. Topamax is manufactured by Janssen Pharmaceuticals, Inc. of Titusville, NJ.

“Migraine headaches can impact school performance, social interactions, and family life,” said Eric Bastings, MD, deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “Adding dosing and safety information for the adolescent age group to the drug’s prescribing information will help to inform healthcare professionals and patients in making treatment choices.”

The FDA noted that about 12% of the U.S. population experiences migraine headaches, and, with many patients experiencing their first migraine attack before reaching adulthood, the condition can be as disabling in teenagers as in adults.

Topamax’s safety and effectiveness in preventing migraine headaches in adolescents ages 12 to 17 was established in a clinical trial that enrolled 103 participants. Those treated with Topamax experienced a decrease in the frequency of migraine of approximately 72% compared with 44% in participants receiving a placebo.

The most common adverse reactions with the approved dose of Topamax (100 milligrams) were paresthesia, upper respiratory infection, anorexia and abdominal pain.

Topamax is required to be dispensed with a Medication Guide cautioning that topamax and all anti-epileptic drugs may increase the risk of suicidal thoughts and behavior. Patients should be advised of the need to be alert for the emergence of, or worsening of, the signs and symptoms of depression, or unusual changes in mood or behavior, the FDA said.

Topamax also increases the risk of the development of oral clefts in infants born to women who take the drug during pregnancy. The benefits and risks of Topamax should be carefully weighed before using it in women of childbearing age, the FDA warned, noting that, if a decision is made to use the medication by a woman of childbearing age, effective birth control should be used.

Related Articles

Lobectomy Still Has Significant Survival Benefit in Early NSCLC

While increased use of stereotactic body radiation might have played a key role in doubling survival rates for early-stage non-small cell lung cancer (NSCLC) among veterans between 2001 and 2010 compared to conventional radiation, a new study confirms that isn’t always the best way to assure longer survival.

VA Hospitals First to Publicly Report Opioid Prescribing Rates

In January, the VA became the first hospital system in the United States to publicly post opioid prescribing rates.

U.S. Medicine Recommends

More From 2014 issues

2014 Issues

VA Slammed for Slow Action Against Officials Behind Wait-Time Scandal

Legislators: Only Four Senior Executives Removed by Mid-November

2014 Issues

VA Launches Largest Overhaul Ever as McDonald Pushes Reforms

WASHINGTON - New VA Secretary Robert McDonald continues to methodically tackle the issues that have caused a breakdown in efficient veteran care over the last few years, now pushing the agency to undertake the largest reorganization since its founding.

2014 Issues

VA’s IT Security Controls Cited for 15th Year in a Row

Controversial Scheduling System Will Be Replaced in 2015

2014 Issues

Study Offers New Statistics on How Many OEF/OIF Veterans Have PTSD

BRONX, NY — For patients with chronic kidney disease (CKD), living more than 30 miles from their nephrologist is associated with many unfavorable outcomes. They have lower rates of clinic visit adherence, more limited access... View Article

2014 Issues

Danger of Pneumonia Increases with Veterans’ Worsened Health Status

BRONX, NY — For patients with chronic kidney disease (CKD), living more than 30 miles from their nephrologist is associated with many unfavorable outcomes. They have lower rates of clinic visit adherence, more limited access... View Article

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up